Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $60.4 million.

  • Stoke Therapeutics' Shares Outstanding (Diluted Average) rose 720.01% to $60.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.4 million, marking a year-over-year increase of 720.01%. This contributed to the annual value of $54.0 million for FY2024, which is 2276.18% up from last year.
  • Per Stoke Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $60.4 million for Q3 2025, which was up 720.01% from $59.7 million recorded in Q2 2025.
  • In the past 5 years, Stoke Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $60.4 million in Q3 2025 and a low of $37.4 million during Q1 2022
  • For the 4-year period, Stoke Therapeutics' Shares Outstanding (Diluted Average) averaged around $48.1 million, with its median value being $44.3 million (2023).
  • Over the last 5 years, Stoke Therapeutics' Shares Outstanding (Diluted Average) had its largest YoY gain of 2843.8% in 2025, and its largest YoY loss of 702.14% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $38.9 million in 2022, then grew by 13.1% to $44.0 million in 2023, then rose by 22.76% to $54.0 million in 2024, then grew by 11.83% to $60.4 million in 2025.
  • Its last three reported values are $60.4 million in Q3 2025, $59.7 million for Q2 2025, and $59.4 million during Q1 2025.